SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal shines on starting limited operations at manufacturing facilities

07 Apr 2020 Evaluate

Hikal is currently trading at Rs. 79.50, up by 5.80 points or 7.87% from its previous closing of Rs. 73.70 on the BSE.

The scrip opened at Rs. 79.50 and has touched a high and low of Rs. 81.05 and Rs. 77.00 respectively.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 187.15 on 16-Apr-2019 and a 52 week low of Rs. 57.00 on 25-Mar-2020.

Last one week high and low of the scrip stood at Rs. 81.05 and Rs. 67.00 respectively. The current market cap of the company is Rs. 908.73 crore.

The promoters holding in the company stood at 68.77%, while Institutions and Non-Institutions held 6.80% and 24.43% respectively.

Hikal has started limited operations on April 05, 2020, at all its manufacturing factories in Taloja (Maharashtra), Mahad (Maharashtra), Panoli (Gujarat), Bengaluru (Karnataka) and the R&D facility located in Pune (Maharashtra). The company has received permission from the government authorities to restart its operations since it is provider of the essential services (Pharmaceutical and Continuous Industries) which are exempted from the lockdown.

The company expects operations to ramp up over the next several days and is ensuring compliance with the directives issued by the Central Government, State Governments and local government and is maintaining social distancing and taking the required precautions for all its staff. Due to the continued restriction in the movement of goods and people by the government, the company will not be able to operate at its optimal capacity. The company remains committed to the health and safety of its employees, their families and communities in which they operate.

Hikal is engaged in R&D, manufacturing and marketing of fine chemicals for the Pharmaceutical and Agrochemical industries

Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×